Journal of Clinical Oncology · 2011 · 773 citations · 30 references
MedicineOncologyPharmacologyChemotherapyGenitourinary OncologyUrologic OncologyBladder CancerGenitourinary Cancer PharmacotherapyChemotherapy Response AssessmentGlomerular Filtration Rate ComparisonGlomerular Filtration Rate MeasurementImpaired Kidney FunctionPlatinum-based CombinationsRenal Function CovariatesRenal Function EvaluationUrothelial Dysfunction
PURPOSE: This is the first randomized phase II/III trial comparing two carboplatin-based chemotherapy regimens in patients with urothelial cancer who are ineligible ("unfit") for cisplatin chemotherapy. PATIENTS AND METHODS: The primary objective of the phase III part of this study was to compare the overall survival (OS) of chemotherapy-naive patients with measurable disease and an impaired renal function (glomerular filtration rate < 60 but > 30 mL/min) and/or performance score of 2 who were randomly assigned to receive either gemcitabine/carboplatin (GC) or methotrexate/carboplatin/vinblastine (M-CAVI). To detect an increase of 50% in median survival with GC compared with M-CAVI (13.5 v 9 months) based on a two-sided log-rank test at error rates α = .05 and β = .20, 225 patients were required. Secondary end points were overall response rate (ORR), progression-free survival (PFS), toxicity, and quality of life. RESULTS: In all, 238 patients were randomly assigned by 29 institutions over a period of 7 years. The median follow-up was 4.5 years. Best ORRs were 41.2% (36.1% confirmed response) for patients receiving GC versus 30.3% (21.0% confirmed response) for patients receiving M-CAVI (P = .08). Median OS was 9.3 months in the GC arm and 8.1 months in the M-CAVI arm (P = .64). There was no difference in PFS (P = .78) between the two arms. Severe acute toxicity (death, grade 4 thrombocytopenia with bleeding, grade 3 or 4 renal toxicity, neutropenic fever, or mucositis) was observed in 9.3% of patients receiving GC and 21.2% of patients receiving M-CAVI. CONCLUSION: There were no significant differences in efficacy between the two treatment groups. The incidence of severe acute toxicities was higher for those receiving M-CAVI.
30
Hans von der Maase, Steen Werner Hansen, J.T. Roberts et al. · Journal of Clinical Oncology · 2000 · 2.3K citations · Full text
Medicine, Oncology, Pharmacology +11
Hans von der Maase, Lisa Sengeløv, J.T. Roberts et al. · Journal of Clinical Oncology · 2005 · 1.9K citations
Management of Cancer in the Older Person: A Practical Approach
Lodovico Balducci, Martine Extermann · The Oncologist · 2000 · 944 citations